- Home
- BLNK vs FHTX Comparison
BLNK vs FHTX Comparison
Compare BLNK & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- FHTX
- Stock Information
- Founded
- BLNK 2009
- FHTX 2015
- Country
- BLNK United States
- FHTX United States
- Employees
- BLNK N/A
- FHTX N/A
- Industry
- BLNK Industrial Specialties
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- BLNK Consumer Discretionary
- FHTX Health Care
- Exchange
- BLNK Nasdaq
- FHTX Nasdaq
- Market Cap
- BLNK 295.1M
- FHTX 517.9M
- IPO Year
- BLNK N/A
- FHTX 2020
- Fundamental
- Price
- BLNK $2.11
- FHTX $7.23
- Analyst Decision
- BLNK Strong Buy
- FHTX Strong Buy
- Analyst Count
- BLNK 7
- FHTX 5
- Target Price
- BLNK $5.79
- FHTX $16.00
- AVG Volume (30 Days)
- BLNK 4.4M
- FHTX 133.0K
- Earning Date
- BLNK 11-07-2024
- FHTX 10-31-2024
- Dividend Yield
- BLNK N/A
- FHTX N/A
- EPS Growth
- BLNK N/A
- FHTX N/A
- EPS
- BLNK N/A
- FHTX N/A
- Revenue
- BLNK $156,918,000.00
- FHTX $35,185,000.00
- Revenue This Year
- BLNK $6.96
- FHTX N/A
- Revenue Next Year
- BLNK $31.64
- FHTX $15.40
- P/E Ratio
- BLNK N/A
- FHTX N/A
- Revenue Growth
- BLNK 66.29
- FHTX 61.95
- 52 Week Low
- BLNK $1.53
- FHTX $2.70
- 52 Week High
- BLNK $4.66
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- BLNK 62.35
- FHTX 41.45
- Support Level
- BLNK $1.63
- FHTX $7.24
- Resistance Level
- BLNK $2.14
- FHTX $8.35
- Average True Range (ATR)
- BLNK 0.12
- FHTX 0.57
- MACD
- BLNK 0.04
- FHTX -0.08
- Stochastic Oscillator
- BLNK 94.12
- FHTX 16.02
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns majority revenue from U.S.A.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.